# **Instruction manual**

# **Contents**

1. Intended Use	1
2. Clinical Applications and Principle of the Assay	1
3. Kit Contents	2
4. Storage and Shelf Life	2
5. Precautions of Use	3
6. Sample Collection, Handling and Storage	3
7. Assay Procedure	4
8. Qualitative Interpretation	5
9. Technical Data	6
0. Performance Data	6-7
11. Literature	7
A : Pipetting scheme	8
B : Test Procedure	9

002 : 2007-08-28 REF 3116 DANA-Pro

#### 1. Intended Use

**AESKULISA DANA-Pro** is a solid phase enzyme immunoassay for the separate qualitative detection of IgG antibodies against eight cellular and nuclear antigens in human serum. The wells are separately coated with recombinant dsDNA, 70 kDa U1 snRNP, SS-B, SS-A 52 kDa, ScI 70, centromere protein B (CenpB), Jo-1 and highly purified native human Sm and SS-A 60 kDa.

The assay is a tool in the differential diagnosis of systemic rheumatic diseases.

# 2. Clinical Application and Principle of the Assay

Anti-nuclear antibodies (ANA) are an important tool for the differential diagnosis of systemic rheumatic diseases. Indirect immunofluorescence test (IFT) on eucaryotic cells like HeLa has been the established method for the detection of ANAs. Single antibody specificities are distinguished by fluorescence patterns but more specific testing by ELISAs employing the target antigens are available too for a simple and reliable differentiation of ANAs.

ANAs are especially found in active and inactive systemic lupus erythematosus (SLE), mixed connective tissue diseases (MCTD), scleroderma, Sjögren's syndrome, polymyositis.

## **ANA Antibodies against:**

- double stranded DNA (dsDNA) are directed against the phosphat units of the DNA. Antibodies against dsDNA are found during active phases of SLE and correlated with the severity of the disease. Anti-dsDNA antibodies have been established as 1 of the 11 ACR-criteria for the diagnosis of SLE.
- U1 snRNP is directed to the 70 kDa protein of U1 snRNP. They are pathognomic for MCTD but do also occur in SLE. A high titer of antibodies against this antigen is typical for the Sharp-Syndrome.
- Sm (Smith antigen) are directed against core proteins (B,B`, D1-D3, E, F, G) of small nuclear ribonucleoproteins (snRNPs). Anti-Sm as well as antibodies against double stranded DNA (dsDNA) are highly specific for SLE and thus are included in diagnostic and classification criteria for SLE.
- SS-A (Ro; soluble cytomplasmic and/or nuclear ribonucleoproteins of 52 kDa and 60 kDa) and antibodies against SS-B (La; 48 kDa protein associated with RNA polymerase III) are mainly found in high titers for primary and secondary Sjögren's syndrome but also in SLE, congenital heartblock and neonatal lupus.
- ScI-70 are directed against DNA-topoisomerase I. They are highly specific for systemic scleroderma and give a hint for a severe course.
- CenpB (80kDa centromere protein B) are typical for the CREST-Syndrome (69% of CREST-patients), which is a more protracted type of systemic sclerosis
- Jo-1 are directed against histidyl-tRNA synthetase (cytoplasmic protein involved in protein biosynthesis) and are found in 20-40 % of patients with polymyositis and dermatomyositis.

#### Principle of the test

Serum samples diluted 1:101 are incubated in the microplates coated with the specific antigen. Patient's antibodies, if present in the specimen, bind to the antigen. The unbound fraction is washed off in the following step. Afterwards anti-human immunoglobulins conjugated to horseradish peroxidase (conjugate) are incubated and react with the antigen-antibody complex of the samples in the microplates. Unbound conjugate is washed off in the following step. Addition of TMB-substrate generates an enzymatic colorimetric (blue) reaction, which is stopped by diluted acid (color changes to yellow). The rate of color formation from the chromogen is a function of the amount of conjugate bound to the antigen-antibody complex and this is proportional to the initial concentration of the respective antibodies in the patient sample.

Page 1 of 9 002 : 2007-08-28 REF 3116 DANA-Pro

#### 3. Kit Contents

#### To be reconstituted:

5x Sample Buffer 1 vial, 20 ml - 5x concentrated (capped white: yellow solution)

Containing: Tris, NaCl, BSA, sodium azide < 0.1% (preservative)

50x Wash Buffer 1 vial, 20 ml - 50x concentrated (capped white: green solution)

Containing: Tris, NaCl, Tween 20, sodium azide < 0.1% (preservative)

Ready to use:

Negative Control 2 vials, each 1.8 ml (capped green: colorless solution)

Containing: Human serum (diluted), sodium azide < 0.1% (preservative)

Cut-off Calibrators 8 vials antigen specific (A-H), 1.5 ml each (capped white: yellow solution)

Containing: Human serum (diluted), sodium azide < 0.1% (preservative)

Conjugate 1 vial,15 ml lgG (capped blue: blue solution)

Containing: Anti-human immunoglobulins conjugated to horseradish peroxidase

TMB Substrate 1 vial, 15 ml (capped black)

Containing: Stabilized TMB/H<sub>2</sub>O<sub>2</sub>

Stop Solution 1 vial, 15 ml (capped white: colorless solution)

Containing: 1M Hydrochloric Acid

Microtiterplate 12x8 well strips with breakaway microwells

Coating see paragraph 1

#### Material required but not provided:

Microtiter plate reader 450 nm reading filter and optional 620 nm reference filter (600-690 nm). Glass ware(cylinder 100-1000ml), test tubes for dilutions. Vortex mixer, precision pipettes (10, 100, 200, 500, 1000  $\mu$ l) or adjustable multipipette (100-1000ml). Microplate washing device (300  $\mu$ l repeating or multichannel pipette or automated system), adsorbent paper.

Our tests are designed to be used with purified water according to the definition of the United States Pharmacopeia (USP 26 - NF 21) and the European Pharmacopeia (Eur.Ph. 4th ed.).

# 4. Storage and Shelf Life

Store all reagents and the microplate at 2-8°C/35-46°F, in their original containers. Once prepared, reconstituted solutions are stable for 1 month at 4°C, at least. **Reagents and the microplate shall be used within the expiry date indicated on each component, only. Avoid intense exposure of TMB solution to light. Store microplates in designated foil, including the desiccant, and seal tightly.** 

Page 2 of 9 002 : 2007-08-28 REF 3116 DANA-Pro

#### 5. Precautions of Use

#### 5.1 Health hazard data

This product is for **IN VITRO DIAGNOSTIC USE** only. Thus, only staff trained and specially advised in methods of in vitro diagnostics may perform the kit. Although this product is not considered particularly toxic or dangerous in conditions of normal use, refer to the following for maximum safety:

#### Recommendations and precautions

This kit contains potentially hazardous components. Though kit reagents are not classified being irritant to eyes and skin we recommend to avoid contact with eyes and skin and wear disposable gloves. WARNING! Calibrators, Controls and Buffers contain sodium azide (NaN<sub>3</sub>) as a preservative. NaN<sub>3</sub> may be toxic if ingested or adsorbed by skin or eyes. NaN<sub>3</sub> may react with lead and copper plumbing to form highly explosive metal azides. On disposal, flush with a large volume of water to prevent azide

build-up. Please refer to decontamination procedures as outlined by CDC or other local/national guide-

lines.

Do not smoke, eat or drink when manipulating the kit.

Do not pipette by mouth.

All human source material used for some reagents of this kit (controls, standards e.g.) has been tested by approved methods and found negative for HbsAg, Hepatitis C and HIV 1. However, no test can guarantee the absence of viral agents in such material completely. Thus handle kit controls, standards and patient samples as if capable of transmitting infectious diseases and according to national requirements.

#### 5.2 General directions for use

Do not mix or substitute reagents or microplates from different lot numbers. This may lead to variations in the results.

Allow all components to reach room temperature (20-32°C/68-89.6°F) before use, mix well and follow the recommended incubation scheme for an optimum performance of the test.

Incubation: We recommend test performance at 30°C/86°F for automated systems.

Never expose components to higher temperature than 37°C/98.6 °F.

Always pipette substrate solution with brand new tips only. Protect this reagent from light. Never pipette conjugate with tips used with other reagents prior.

A definite clinical diagnosis should not be based on the results of the performed test only, but should be made by the physician after all clinical and laboratory findings have been evaluated. The diagnosis is to be verified using different diagnostic methods.

# 6. Sample Collection, Handling and Storage

Use preferentially freshly collected serum samples. Blood withdrawal must follow national requirements.

Do not use icteric, lipemic, hemolysed or bacterially contaminated samples. Sera with particles should be cleared by low speed centrifugation (<1000 x g). Blood samples should be collected in clean, dry and empty tubes. After separation, the serum samples should be used immediately, respectively stored tightly closed at  $2-8^{\circ}\text{C}/35-46^{\circ}\text{F}$  up to three days, or frozen at  $-20^{\circ}\text{C}/-4^{\circ}\text{F}$  for longer periods.

Page 3 of 9 002 : 2007-08-28 REF 3116 DANA-Pro

## 7. Assay Procedure

#### 7.1 Preparations prior to pipetting

Dilute concentrated reagents:

Dilute the concentrated sample buffer 1:5 with distilled water (e.g. 20 ml plus 80 ml). Dilute the concentrated wash buffer 1:50 with distilled water (e.g. 20 ml plus 980 ml).

#### Samples:

Dilute serum samples 1:101 with sample buffer (1x) e.g. 1000 µl sample buffer (1x) + 10 µl serum. Mix well!

#### Washing:

Prepare 20 ml of diluted wash buffer (1x) per 8 wells or 200 ml for 96 wells e.g. 4 ml concentrate plus 196 ml distilled water.

#### Automated washing:

Consider excess volumes required for setting up the instrument and dead volume of robot pipette.

#### Manual washing:

Discard liquid from wells by inverting the plate. Knock the microwell frame with wells downside vigorously on clean adsorbent paper. Pipette 300 µl of diluted wash buffer into each well, wait for 20 seconds. Repeat the whole procedure twice again.

#### Microplates:

Calculate the number of wells required for the test. Remove unused wells from the frame, replace and store in the provided plastic bag, together with desiccant, seal tightly (2-8°C/35-46°F).

#### 7.2 Work flow

For pipetting scheme see Annex A, for test procedure see Annex B: We recommend pipetting samples and calibrators in duplicate.

Cut-off calibrator should be used for qualitative testing only.

- Pipette 100 μl of each patient's diluted serum into the designated microwells.
- Pipette 100 µl of each cut-off calibrator and negativ control into the designated wells.
- Incubate for 30 minutes at 20-32°C/68-89.6°F.
- Wash 3x with 300 µl washing buffer (diluted 1:50).
- Pipette 100 μl conjugate into each well.
- Incubate for 30 minutes at 20-32°C/68-89.6°F.
- Wash 3x with 300 µl washing buffer (diluted 1:50).
- Pipette 100 µl TMB substrate into each well.
- Incubate for 30 minutes at 20-32°C/68-89.6°F, protected from intense light.
- Pipette 100 µl stop solution into each well, using the same order as pipetting the substrate.
- Incubate 5 minutes minimum.
- Agitate plate carefully for 5 sec.
- Read absorbance at 450 nm (optionally 450/620 nm) within 30 minutes.

Page 4 of 9 002 : 2007-08-28 REF 3116 DANA-Pro

# 8. Qualitative Interpretation

Read the optical density of the cut-off calibrator and the patient samples. Multiply the OD of the cutoff calibrator by the parameterspecific factor, provided with the lot specific QC certificate. Compare patient's OD with the calculated parameter OD cut-off value. For qualitative interpretation we recommend to consider sera within a range of 20% around the cut-off value as equivocal. All samples with higher ODs are considered positive, samples with lower ODs are considered negative.

ANA-8Profil	O.D. 450/620 nm
Negative Control	0.033
Cut-off Calibrator	0.550

Example of interpretation

Measured:

We recommend pipetting cut-off calibrator for each run.

QC-Certificate: Jo-1 Factor: 0.95

OD<sub>Cut-off Calibrator</sub> (Jo-1): OD<sub>Cut-off Parameter</sub> (Jo-1): Calculation:  $0.550 \times 0.95 =$ 0.5225

0.550

OD  $_{Patient}$  < 0.8 x OD  $_{Cut-off\ Parameter}$  = 0.8 x 0.5225 = **Negative:** 0.418

OD Patient  $> 1.2 \times$  OD Cut-off Parameter  $= 1.2 \times 0.5225 =$ Positive: 0.627

0.418 ≤ ≤ 0.627 Equivocal: OD Patient

ID	Sample	OD - Calculation	Interpretation
Nr.	OD Jo-1		
1	0.99	> 0.627	→ Positive
2	0.49	≥ <b>0.418</b> und ≤ <b>0.627</b>	→ Equivocal
3	0.27	< 0.418	Negative

Do not use this example for interpreting patients results!

For lot specific data, see enclosed quality control leaflet. Medical laboratories might perform an inhouse Quality Control by using own controls and/or internal pooled sera, as foreseen by EU regulations.

For semi-quantification of the results, each patient-OD value can be expressed by the Index-Value. The Index-Value is calculated by dividing the patient-OD by the cut-off parameter:

> OD (patient sample) Index Value =

OD (cut-off parameter)

Negative: OD-Patient < 0.8 Equvocal:  $0.8 \le OD$ -Patient  $\le 1.2$ Positive: OD Patient > 1.2

Page 5 of 9 002:2007-08-28 REF 3116 DANA-Pro

#### 9. Technical Data

Sample material: serum

**Sample volume:** 10 μl of sample diluted 1:101 with 1x sample buffer

**Total incubation time:** 90 minutes at 20-32°C/68-89.6°F

**Storage:** at 2-8°C/35-46°F use original vials, only

Number of determinations: 96 tests

#### 10. Performance Data

#### 10.1 Specificity and sensitivity

The microplate is coated with highly purified and/or recombinant antigens (dsDNA, U1 snRNP 70kDa, Sm, SS-A, SS-B, Scl-70, CenpB, Jo-1). No crossreactivities to other autoantigens have been found. ANA are not specific for SLE but are found in variety of rheumatic diseases. Detection of ANA is a very sensitive marker for an active SLE and is positive in >99% of all cases.

#### 10.2 Linearity

Chosen sera have been tested with this kit and found to dilute linearly. However, due to the heterogeneous nature of human autoantibodies there might be samples that do not follow this rule.

Sample		measured	expected	
No.	Dilution	concentration	concentration	Recovery
ScI-70	Factor	(U/ml)	(U/ml)	(%)
1	1 / 100	6.1	6.1	100.0
	1 / 200	3.1	3.05	101.6
	1 / 400	1.49	1.53	97.3
	1 / 800	0.71	0.76	93.4
2	1 / 100	3.2	3.4	94.1
	1 / 200	1.6	1.7	94.1
	1 / 400	0.81	0.85	95.3
	1 / 800	0.41	0.43	95.4

Page 6 of 9 002 : 2007-08-28 REF 3116 DANA-Pro

#### 10.3 Precision

To determine the precision of the assay, the variability (intra and inter-assay) was assessed by examining its reproducibility on three serum samples selected to represent a range over the standard curve.

In	tra-Assay	
DANA-Pro	Mean OD	CV (%)
	Ratio	
dsDNA	2.1	0.4
U1RNP	3.1	0.8
Sm	1.8	1.0
SSA	3.5	1.2
SSB	2.8	1.0
Scl-70	1.2	1.5
CenpB	1.5	1.1
Jo-1	1.0	1.2

lı	nter-Assay	
DANA-Pro	Mean OD	CV (%)
	Ratio	
dsDNA	4.2	1.0
U1RNP	3.2	0.8
Sm	4.1	1.1
SSA	3.9	0.9
SSB	1.5	0.7
Scl-70	1.4	1.9
CenpB	2.5	1.2
Jo-1	2.4	8.0

#### 10.4 Calibration

The AESKULISA DANA-Pro is calibrated against reference sera from the CDC (Centers for Disease Control and Prevention) Atlanta.

### 11. Literature

#### 1. Antinuclear antibody.

The Lancet 1984, Sept. 15: 611-13.

### 2. Froelich CH, Wallmann H, Skosey JL and Teodorescu M.

Clinical value of an integrated ELISA system for the detection of 6 autoantibodies. The Journal of Rheumatology 1990; 17 (2): 192-200.

#### 3. Mierau R, Genth E.

Autoantikörper bei systemischem Lupus erythematodes und verwandten Erkrankungen.

In: Thomas L. (Hrsg.) Labor und Diagnose

TH-Books, Frankfurt, 1998, 5. Auflage: 843-851.

#### 4. Schmolke M, Oppermann M, Helmke K, Guder WG.

Antibody determination against ENA- a challenge for the routine laboratory. Poster P59, 5 th Dresden Symposium on Autoantibodies, 2000.

Page 7 of 9 002 : 2007-08-28 REF 3116 DANA-Pro

# **ANNEX A: Pipetting scheme**

We suggest pipetting calibrators, controls and samples as follows:

Antigen		1	2	3	4	5	6	7	8	9	10	11	12
dsDNA	Α	CCA	NC	P1	P2	P3							
U1-70-RNP	В	CCB	NC	P1	P2	P3							
Sm	С	CCC	NC	P1	P2	P3							
SS-A	D	CCD	NC	P1	P2	P3							
SS-B	Ε	CCE	NC	P1	P2	P3							
Scl-70	F	CCF	NC	P1	P2	P3							
CenpB	G	CCG	NC	P1	P2	P3							
Jo-1	Н	CCH	NC	P1	P2	P3					·		


CCA: cut-off calibrator A; CCB: cut-off calibrator B; CCC: cut-off calibrator C; CCD: cut-off calibrator D; CCE: cut-off calibrator E; CCF: cut-off calibrator F; CCG: cut-off calibrator G; CCH: cut-off calibrator H.


NC: negative calibrator


P1: patient 1 P2: patient 2 P3: patient 3

Page 8 of 9 002 : 2007-08-28 REF 3116 DANA-Pro

# **Annex B: Test Procedure**







Assay/Test:			l In	Incubation / Inkub.:	nkub. :	1.	mim		Date/	Date/ Datum:		
Temperatuı	Temperature/Temperatur:	ur:	Jo-	).		.5	mim	:5	41 I/ 021 140 420	40,40		
Name:						3.	min_	ā	Signature/ Untersenrin.			1
		7	3	4	5	9	7	∞	6	10	11	12
ds-DNA	cut-off calibrator	negative control										
U1-70	cut-off negativ	negative control										
Sm	cut-off negativ	negative control										
SSA 52/60	cut-off calibrator	negative control										
SSB	cut-off calibrator											
Scl-70	cut-off calibrator											
Cenp B	cut-off calibrator											
Jo-1	cut-off calibrator	negative control										

**AESKU**.DIAGNOSTICS GmbH 55234 Wendelsheim - Mikroforum Ring 2, Germany Phone: + 49-6734-96270, Fax: + 49-6734-962727 DANA-Pro

	_	
	◆ Diagnosi in vitro	◆ For in vitro diagnostic use
IVD	◆ Pour diagnostic in vitro	<ul> <li>Para uso diagnóstico in vitro</li> </ul>
וטעו	◆ In Vitro Diagnostikum	♦ In Vitro Διαγνωστικό μέσο
	◆ Para uso Diagnóstico in vitro	
	♦ Numero d'ordine	♦ Cataloge number
DEE	♦ Référence Catalogue	♦ Numéro de catálogo
REF	♦ Bestellnummer	<ul><li>◆ Αριθμός παραγγελίας</li></ul>
	♦ Número de catálogo	
	Descrizione lotto	♦ Lot
	◆ Lot	♦ Lote
LOT	◆ Chargen Bezeichnung	<ul><li>Χαρακτηρισμός παρτίδας</li></ul>
	◆ Lote	- Pro 10 (Prop. 1977)
	◆ Conformità europea	◆ EC Declaration of Conformity
(€	◆ Déclaration CE de Conformité	◆ Ec Declaration of Conformity     ◆ Declaración CE de Conformidad
( )	Europäische Konformität	<ul> <li>Φ Ευρωπαϊκή συμφωνία</li> </ul>
	<ul> <li>Déclaração CE de Conformidade</li> </ul>	τ Ευρωπαίκη συμφωνία
		▲ 06 tasts
\06/	96 determinazioni     06 teete	♦ 96 tests
90/	♦ 96 tests	♦ 96 pruebas
$\bigvee$	◆ 96 Bestimmungen     ◆ 96 Testes	<ul><li>◆ 96 προσδιορισμοί</li></ul>
	♦ 96 Testes	
	♦ Rispettare le istruzioni per l'uso	♦ See instructions for use
l i	♦ Voir les instructions d'utilisation	♦ Ver las instrucciones de uso
	Gebrauchsanweisung beachten	<ul><li>Λάβετε υπόψη τις οδηγίες χρήσης</li></ul>
}	♦ Ver as instrucões de uso	
	◆ Da utilizzarsi entro	♦ Use by
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	◆ Utilise avant le	◆ Utilizar antes de
	♦ Verwendbar bis	<ul><li>Χρήση μέχρι</li></ul>
	◆ Utilizar antes de	
	◆ Conservare a 2-8°C	♦ Store at 2-8°C (35-46°F)
<b>Ω</b> ~+8°C	♦ Conserver à 2-8°C	♦ Conservar a 2-8°C
+2°C- <b>/</b>	◆ Lagerung bei 2-8°C	♦ Φυλάσσεται στους 2-8°C
•	◆ Conservar entre 2-8°C	<b>,</b>
	♦ Prodotto da	Manufactured by
	♦ Frodotto da ♦ Fabriqué par	◆ Fabricado por
	Hergestellt von	<ul><li>▼ Γαυτισαύο μοι</li><li>♦ Κατασκευάζεται από</li></ul>
	Fabricado por	+ manaoneougenarumo
	•	▲ Cut off Calibrator
22.211	Calibratore cut-off     Etalon Souil	◆ Cut off Calibrator  ◆ Calibrator do cut off
ICO-CAI	Etalon Seuil     Crongwert Kelibrator	♦ Calibrador de cut-off
00 0/ L	Grenzwert Kalibrator     Gelibrader de cut off	<ul> <li>Οριακός ορός Αντιδραστήριο βαθμονόμησης</li> </ul>
	Calibrador de cut-off	
	◆ Controllo positivo	♦ Positive Control
CON +	◆ Contrôle Positif	◆ Control Positivo
0011	◆ Positiv Kontrolle	<ul><li>Φετικός ορός ελέγχου</li></ul>
	◆ Controlo positivo	
	<ul> <li>◆ Controllo negativo</li> </ul>	♦ Negative Control
CON	◆ Contrôle Négatif	◆ Control Negativo
CON	♦ Negativ Kontrolle	<ul> <li>Αρνητικός ορός ελέγχου</li> </ul>
	◆ Controlo negativo	
	◆ Calibratore	◆ Calibrator
CAL	♦ Etalon	<ul> <li>◆ Calibrador</li> </ul>
CAL	♦ Kalibrator	<ul> <li>Αντιδραστήριο βαθμονόμησης</li> </ul>
	<ul><li>◆ Calibrador</li></ul>	
	♦ Recupero	♦ Recovery
DC	♦ Corrélation	♦ Recuperado
KC	♦ Wiederfindung	♦ Ανάκτηση
	♦ Recuperação	
	♦ Coniugato	♦ Conjugate
2011	◆ Conjugé	◆ Conjugado
CONJ	♦ Konjugat	<ul><li>Σύζευγμα</li></ul>
	◆ Conjugado	· - 2 11: -
	Micropiastra rivestita	◆ Coated microtiter plate
	Microplaque sensibilisée	Microplaca sensibilizada
MP	Beschichtete Mikrotiterplatte	<ul> <li>νιιστοριασα sensibilizada</li> <li>Επικαλυμμένη μικροπλάκα</li> </ul>
	Microplaca revestida	▼ Επικαλομμένη μικροπλακά
		▲ Coated pippleto
	Piastra ad aghi rivestita     Piantata sansibiliséa	◆ Coated pinplate  ◆ Pinplate specifilizada
PINP	◆ Pinplate sensibilisée  ▲ Resphishtete Pinplatte	♦ Pinplate sensibilizada
1 1141	Beschichtete Pinplatte     Binplate revestide	◆ Επικαλυμμένη πλάκα Pin
	Pinplate revestida	
	◆ Tampone di lavaggio     →	♦ Wash buffer
WASHB 50x	◆ Tampon de Lavage	♦ Solución de lavado
אססן עו וסראיי	♦ Waschpuffer	<ul><li>◆ Ρυθμιστικό διάλυμα πλύσης</li></ul>
	♦ Solução de lavagem	
	<ul> <li>◆ Tampone substrato</li> </ul>	<ul> <li>Substrate buffer</li> </ul>
CLID	◆ Substrat	<ul> <li>Tampón sustrato</li> </ul>
SUB	<ul> <li>◆ Substratpuffer</li> </ul>	<ul> <li>Ρυθμιστικό διάλυμα υποστρώματος</li> </ul>
	♦ Substrato	
	♦ Reagente bloccante	♦ Stop solution
OTOB	♦ Solution d'Arrêt	♦ Solución de parada
STOP	◆ Stopreagenz	<ul> <li>Αντιδραστήριο διακοπής αντίδρασης</li> </ul>
	. •	
0101	<ul> <li>♦ Solução de paragem</li> </ul>	
0101	◆ Solucão de paragem     ◆ Tampone campione	Sample huffer
	◆ Tampone campione	♦ Sample buffer
	◆ Tampone campione ◆ Tampon Echantillons	♦ Tampón Muestras
SB   5x	◆ Tampone campione	•